# Marker Therapeutics

Source: https://onco.cc/companies/marker-therapeutics/  
OnCo record `marker-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Marker grows a patient's own T cells that naturally recognise several tumour proteins at once, without genetic engineering, and gives them back as a treatment. Its lead product has shown responses in relapsed lymphoma and is moving into pancreatic cancer.

## Summary

Marker Therapeutics is a Houston clinical-stage immuno-oncology company developing Multi-Antigen Recognizing (MAR)-T cell therapies, non-engineered T-cell products enriched for reactivity against several tumour-associated antigens. Lead candidate MT-601 is in the phase 1 APOLLO study in relapsed non-Hodgkin lymphoma, where an update reported a 66% objective response rate including 50% complete responses; lymphodepletion was shown to enhance MT-601 expansion and persistence, and the study moved into dose expansion in relapsed diffuse large B-cell lymphoma with a further update expected in the second quarter of 2026. Baylor College of Medicine research published in Nature Medicine in early 2026 reported promising results with MAR-T cells in pancreatic cancer, and Marker plans a company-sponsored pancreatic cancer trial. Manufacturing is supported by a collaboration with Cellipont Bioservices. Nasdaq: MRKR.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Houston, TX
- Type: cell-therapy
- Website: https://markertherapeutics.com/
- Ticker: MRKR

## Notes

- No funding round sourced.

## Sources

- Official website: https://markertherapeutics.com/
- Year-end 2025 results (8-K exhibit 99.1, March 2026): https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_ex99-1.htm

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/marker-therapeutics.json